| CAS NO: | 518-34-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 622.75 |
|---|---|
| Formula | C38H42N2O6 |
| CAS No. | 518-34-3 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: <1 mg/mL |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: (11S,31S)-16,36,37,54-tetramethoxy-12,32-dimethyl-11,12,13,14,31,32,33,34-octahydro-2,6-dioxa-1(7,1),3(8,1)-diisoquinolina-5(1,3),7(1,4)-dibenzenacyclooctaphane SMILES Code: COC1=C(C2=C(C=C1OC)CCN(C)[C@]2(C3)[H])OC4=CC5=C(C=C4OC)CCN(C)[C@]5(CC6=CC=C(OC7=CC3=CC=C7OC)C=C6)[H] |
| Synonyms | NSC 77037; Sinomenine A; d-tetrandrine; Fanchinine; Tetrandrine; NSC-77037; NSC77037; (S,S)-(+)-tetrandrine; TTD. |
| In Vitro | In vitro activity: Tetrandrine inhibits voltage-gated Ca2+ currents with an IC50 of 10.1 mM in isolated nerve terminals of the rat neurohypophysis. Tetrandrine is a high-affinity blocker of the type II, maxi-Ca(2+)-activated K+ channel of the rat neurohypophysial terminals with an IC50 of 0.21 mM. Another study shows that Tetrandrine also inhibits Ca(2+)-activated Cl- currents (I(Cl,Ca)) with an IC50 of 5.2 mM. Tetrandrine inhibits the proliferation of human leukemic HL-60 cells via induction of apoptosis. Cell Assay: Huh7, HCCLM9 and Hep3B cells are seeded in a 96-well plate at a cell density of 5 × 103 cells/well. The cells are treated with the indicated concentrations (0-4 μM) of Tetrandrine (NSC-77037) for 24 h. The cells are subsequently stained with 20 μL of MTS for 1-2 h, and the plates are read at 490 nm on a BioTek ELx800. |
|---|---|
| In Vivo | To evaluate the effect of Tetrandrine (NSC-77037) on the inhibition of tumor metastasis in vivo, HCCLM9 subcutaneous tumor xenograft models is established with athymic nude mice. When the tumor volume reach approximately 50 mm3, nude mice are orally administered vehicle or Tetrandrine (NSC-77037) (30 mg/kg) every other day for 37 days. Tetrandrine (NSC-77037) treatment inhibits tumor growth by reducing the tumor volume and weight. |
| Animal model | Mice |
| Formulation & Dosage | Four-week-old male athymic BALB/c nu/nu SPF mice (body weight range from 18 g to 20 g) are used. HCCLM9 WT and HCCLM9 ATG7 KO cells (5 million) resuspended in 0.2 mL of PBS are subcutaneously implanted into the right flank of each mouse. When the tumor volume reach approximately 50 mm3, the tumor-bearing mice are randomly divided into control and treatment groups (n = 6). The control and treatment groups are administered oral injection of vehicle (0.5% methylcellulose) and Tetrandrine at 30 mg/kg of body weight every other day for 37 days. During the treatment, the tumor volumes are measured every day and are calculated. |
| References | Pflugers Arch. 1992 Sep;421(6):558-65; Acta Pharmacol Sin. 2004 Mar;25(3):327-33; J Exp Clin Cancer Res. 2018 Jan 15;37(1):7. |
m.cnreagent.com